Correction to: Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with inflammatory bowel disease

Eirini Theodoraki¹ · Eleni Orfanoudaki¹ · Kalliopi Foteinogiannopoulou¹ · Nikolaos-Panagiotis Andreou² · Maria Gazouli² · Ioannis E. Koutroubakis¹

Published online: 29 January 2022

© Springer-Verlag GmbH Germany, part of Springer Nature 2022

Correction to: International Journal of Colorectal Disease
<https://doi.org/10.1007/s00384-021-04091-6>

In the original version of this article, Fig. 3 contained images that were not in correct order. The figure should have appeared as shown below.

The original article can be found online at <https://doi.org/10.1007/s00384-021-04091-6>.

✉ Eirini Theodoraki
eirinith25@yahoo.gr

✉ Ioannis E. Koutroubakis
koutroui@uoc.gr

¹ Department of Gastroenterology, Medical School, University Hospital of Heraklion, University of Crete, P.O. BOX 1352, 71110 Heraklion, Crete, Greece

² Department of Basic Medical Sciences, Laboratory of Biology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Fig. 3 **A** Comparison of IFX **a** TLs and **b** antibodies of anti-ds-DNA (-) (N=42) and anti-ds-DNA (+) (N=8) patients (P=0.24 and P=0.98). **B** Comparison of ADA **a** TLs and **b** antibodies of anti-ds-DNA (-) (N=32) and anti-ds-DNA (+) (N=20) patients (P=0.82 and P=0.79)

The original article has been corrected.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.